{"id":17880,"date":"2023-06-15T01:36:00","date_gmt":"2023-06-14T17:36:00","guid":{"rendered":"https:\/\/flcube.com\/?p=17880"},"modified":"2024-12-14T01:39:12","modified_gmt":"2024-12-13T17:39:12","slug":"ascletis-pharma-inc-ceases-promotion-of-hepatitis-c-products-and-halts-development-of-asc06-and-asc09","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=17880","title":{"rendered":"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09"},"content":{"rendered":"\n<p>China-based Ascletis Pharma Inc., (<a href=\"https:\/\/www.google.com\/finance\/quote\/1672:HKG\">HKG: 1672<\/a>) has announced significant business adjustments, including the decision to cease promoting and marketing its hepatitis C virus (HCV) products, ravidasvir and danoprevir. The decision comes in response to the HCV market&#8217;s challenges, which include the impact of the National Reimbursement Drug List (NRDL), the absence of a position for its product portfolio in the latest HCV guidelines, and a significant decrease in HCV cases and demand due to COVID-19.<\/p>\n\n\n\n<p><strong>Termination of Development for ASC06 and ASC09<\/strong><br>In addition to the changes in their HCV portfolio, Ascletis has also decided to end the development of two investigational candidates, ASC06 and ASC09. ASC06, designed to treat liver cancer through RNA interference delivery technology, faced termination due to the technology becoming outdated and potentially lacking a competitive edge in the future. Despite completing Phase I clinical trials in the US, the drug has not been filed for IND in China. Ascletis plans to replace ASC06 with a small molecule programmed-death ligand 1 (PD-L1) inhibitor, ASC61.<\/p>\n\n\n\n<p><strong>ASC09 Development Halted Due to Market Shifts<\/strong><br>ASC09, an HIV protease inhibitor in-licensed from Janssen in 2013, has completed Phase I clinical studies in combination with ritonavir in China. The development of ASC09 is being terminated as alternative products, such as HIV Entry inhibitor drugs with the same indications, have been approved for marketing in China and have become the mainstream choice for the treatment of HIV type 1 infection. ASC09 is seen to lack competitive advantages over these alternatives.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[189,16,980,64,89],"class_list":["post-17880","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ascletis-pharma","tag-cancer","tag-hkg-1672","tag-rnai-aso","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to cease promoting and marketing its hepatitis C virus (HCV) products, ravidasvir and danoprevir. The decision comes in response to the HCV market&#039;s challenges, which include the impact of the National Reimbursement Drug List (NRDL), the absence of a position for its product portfolio in the latest HCV guidelines, and a significant decrease in HCV cases and demand due to COVID-19.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=17880\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=17880\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-14T17:36:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-13T17:39:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17880#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17880\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09\",\"datePublished\":\"2023-06-14T17:36:00+00:00\",\"dateModified\":\"2024-12-13T17:39:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17880\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascletis Pharma\",\"Cancer\",\"HKG: 1672\",\"RNAi \\\/ ASO\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17880#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17880\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=17880\",\"name\":\"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-06-14T17:36:00+00:00\",\"dateModified\":\"2024-12-13T17:39:12+00:00\",\"description\":\"China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to cease promoting and marketing its hepatitis C virus (HCV) products, ravidasvir and danoprevir. The decision comes in response to the HCV market's challenges, which include the impact of the National Reimbursement Drug List (NRDL), the absence of a position for its product portfolio in the latest HCV guidelines, and a significant decrease in HCV cases and demand due to COVID-19.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17880#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17880\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17880#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09 - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to cease promoting and marketing its hepatitis C virus (HCV) products, ravidasvir and danoprevir. The decision comes in response to the HCV market's challenges, which include the impact of the National Reimbursement Drug List (NRDL), the absence of a position for its product portfolio in the latest HCV guidelines, and a significant decrease in HCV cases and demand due to COVID-19.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=17880","og_locale":"en_US","og_type":"article","og_title":"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=17880","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-06-14T17:36:00+00:00","article_modified_time":"2024-12-13T17:39:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=17880#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=17880"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09","datePublished":"2023-06-14T17:36:00+00:00","dateModified":"2024-12-13T17:39:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=17880"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascletis Pharma","Cancer","HKG: 1672","RNAi \/ ASO","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=17880#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=17880","url":"https:\/\/flcube.com\/?p=17880","name":"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-06-14T17:36:00+00:00","dateModified":"2024-12-13T17:39:12+00:00","description":"China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to cease promoting and marketing its hepatitis C virus (HCV) products, ravidasvir and danoprevir. The decision comes in response to the HCV market's challenges, which include the impact of the National Reimbursement Drug List (NRDL), the absence of a position for its product portfolio in the latest HCV guidelines, and a significant decrease in HCV cases and demand due to COVID-19.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=17880#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=17880"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=17880#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17880"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17880\/revisions"}],"predecessor-version":[{"id":17881,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17880\/revisions\/17881"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}